People
With all the similarities, it should be emphasized that there are several significant differences between the two pandemics.
Under terms of the deal, Aurobindo would pay $900 million upfront with an additional $100 million in milestone payments. However, in a filing with the Securities and Exchange Commission, the company announced it had terminated that agreement.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
On Wednesday, the judge overseeing Holmes’ case set for late July refused to change the trial date after her defense team made the request.
On March 25, the American Medical Association, American Pharmacist Association and Americans Society of Health-System Pharmacists issued a statement in response to media reports that physicians and pharmacists were hoarding supplies of the drugs for their own use.
“Companies active in the fight against COVID-19 will have plenty of funding, and those targeting severe unmet needs will weather the storm better than others. But, for the rest, it will be rough for the next 12 months,” said Otello Stampacchia, founder of Omega Funds.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 1, 2020.
Results from the trial, which will begin dosing on April 6, aren’t likely until September.
In addition to the impact on conferences and large meetings, many companies have implemented restrictions on face-to-face meetings between sales reps and clients.
Doudna announced she is converting a 2,500-square-foot scientific lab at Berkeley’s Innovative Genomics Institute into a lab for testing for the novel coronavirus that causes COVID-19.
PRESS RELEASES